Scarica l'app Stockscreener
1.39
4.14%
-0.06
Dopo l'orario di chiusura:
1.39
Precedente Chiudi:
$1.45
Aprire:
$1.45
Volume 24 ore:
230.15K
Relative Volume:
0.30
Capitalizzazione di mercato:
$43.58M
Reddito:
-
Utile/perdita netta:
$-69.00M
Rapporto P/E:
-0.50
EPS:
-2.78
Flusso di cassa netto:
$-55.26M
1 W Prestazione:
+5.30%
1M Prestazione:
+12.10%
6M Prestazione:
-74.50%
1 anno Prestazione:
-82.62%
Intervallo 1D:
$1.38
$1.4795
Intervallo di 1 settimana:
$1.33
$1.495
Portata 52W:
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Confronta ACRV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.39 | 43.58M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
What analysts say about Acrivon Therapeutics Inc. stockRapid wealth creation - jammulinksnews.com
Is Acrivon Therapeutics Inc. a good long term investmentHigh-octane investment gains - jammulinksnews.com
How high can Acrivon Therapeutics Inc. stock price go in 2025Smart Money Signals - Newser
Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Yahoo Finance
What drives Acrivon Therapeutics Inc. stock priceConsistently superior profits - printweek.in
Is Acrivon Therapeutics Inc. stock a good hedge against inflationSolid Return Trade Selections - beatles.ru
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $17.71 - Defense World
What makes Acrivon Therapeutics Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
How Acrivon Therapeutics Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - GlobeNewswire Inc.
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Trading 0.7% Higher – Still a Buy? - Defense World
Acrivon Therapeutics, Inc.(NasdaqGM: ACRV) dropped from S&P Global BMI Index - MarketScreener
Learn to Evaluate (ACRV) using the Charts - news.stocktradersdaily.com
Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks
Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):